The project consortium, which consists of 68 Australian and international partners, is being led by Prof Wei Zhang from Flinders University and includes researchers from the ARC Centre of Excellence for Electromaterials Science (ACES).
ACES researchers will provide bioengineering and biomaterials expertise for the Marine Bioproducts Cooperative Research Centre (MB-CRC), bringing together the excellence of fabrication skills at the University of Wollongong with the growing research and industry activity in marine bioresources. The MB-CRC includes research, industry and government partners working collaboratively to expand existing enterprises and drive new, high-value products, commercial technologies and employment opportunities around Australia to meet rapidly growing demand for certified, safe and sustainable products.
Funding to fast-track the growth of Australia’s next generation of marine bioproducts industries.
A team of researchers at the ARC Centre of Excellence for Electromaterial Science (ACES) based at the University of Wollongong (UOW), in conjunction with a consortium of 68 Australian and international partners, has been awarded $59 Million in funding in the latest round of grants from the Federal Government’s Cooperative Research Centres program.
The funding will fast-track the growth of Australia’s next generation of marine bioproducts industries and, ACES researchers will provide bioengineering and biomaterials expertise for the Marine Bioproducts Cooperative Research Centre (MB-CRC), bringing together the excellence of fabrication skills at UOW with the growing research and industry activity in marine bioresources.
Synthego, the genome engineering company, today announced the launch of Eclipse™, a new high-throughput cell engineering platform designed to accelerate drug discovery and validation by providing highly predictable CRISPR-engineered cells at scale through the integration of engineering, bioinformatics, and proprietary science. The launch of this unique CRISPR-based platform is driving the company s growing impact in biopharma R&D, reinforcing Synthego s position as the genome engineering leader.
Synthego s Eclipse Platform Enables Scalable CRISPR-based Cell Engineering
CRISPR-engineered cells have a wide range of applications in research and development across disease areas, including in neuroscience and oncology. Synthego created the
Eclipse platform to enhance disease modeling, drug target identification and validation, and accelerate cell therapy manufacturing.
Last Updated:
Cancer Can Now Be Treated Using Living Cells And Synthetic Biology, Researchers Find
Researchers have developed a process that uses parts from a very different kind of toolkit to build complex genetic circuits for cellular engineering. Read here
Northwestern University synthetic biologist Joshua Leonard and his team have made a design-driven process which uses parts from a very different kind of toolkit to build complex genetic circuits for cellular engineering. Using living cells as therapies is of great use in medicines. Many patients have been cured using this new approach. This new discovery would help the bioengineers to make genetic programs using synthetic biology.